150 related articles for article (PubMed ID: 21532549)
1. Dual fronts poised to transform melanoma therapy.
Mullard A
Nat Rev Drug Discov; 2011 May; 10(5):325-6. PubMed ID: 21532549
[No Abstract] [Full Text] [Related]
2. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
3. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
4. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
5. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
6. Melanoma vaccines: possible progress after years of frustration?
Schmidt C
J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
[No Abstract] [Full Text] [Related]
7. Therapy for metastatic melanoma: an overview and update.
Boyle GM
Expert Rev Anticancer Ther; 2011 May; 11(5):725-37. PubMed ID: 21554048
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for cutaneous melanoma.
Nathan FE; Mastrangelo MJ
Semin Oncol; 1995 Dec; 22(6):647-61. PubMed ID: 8539640
[No Abstract] [Full Text] [Related]
9. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
10. Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence.
Hemrajani RH; Kim KB; Amos WR; Mann DE
Melanoma Res; 2007 Aug; 17(4):257-9. PubMed ID: 17625458
[No Abstract] [Full Text] [Related]
11. The systemic treatment of advanced cutaneous melanoma.
Logan TF
Facial Plast Surg Clin North Am; 2003 Feb; 11(1):75-85. PubMed ID: 15062290
[No Abstract] [Full Text] [Related]
12. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
13. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
14. Randomized trials in melanoma: an update.
Eggermont AM
Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
[TBL] [Abstract][Full Text] [Related]
15. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
16. [Comments on the treatment of malignant melanoma].
Zaumseil RP; Wohlrab W
Dermatol Monatsschr; 1977 May; 163(5):367-71. PubMed ID: 881083
[No Abstract] [Full Text] [Related]
17. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
19. [In vitro drug sensitivity profiling in melanoma].
Ugurel S
J Dtsch Dermatol Ges; 2008 Jul; 6(7):611. PubMed ID: 18611186
[No Abstract] [Full Text] [Related]
20. Phase III adjuvant studies in operable malignant melanoma (review).
Lejeune FJ
Anticancer Res; 1987; 7(4B):701-5. PubMed ID: 3314671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
